CLYM19123 / AALL1731 / Kazi
Basic Study Information
Purpose:
This phase III trial studies how well blinatumomab works in combination with chemotherapy
in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia
or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies,
such as blinatumomab, may induce changes in the body's immune system and may interfere
with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as vincristine,
dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine,
doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate.
Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving
blinatumomab and combination chemotherapy may work better than combination chemotherapy
alone in treating patients with B-ALL. This trial also assigns patients into different
chemotherapy treatment regimens based on risk (the chance of cancer returning after
treatment). Treating patients with chemotherapy based on risk may help doctors decide
which patients can best benefit from which chemotherapy treatment regimens.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Rafi Kazi
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search